Key information made simple
This summary needs review. Please check the official study record and contact the research team for details.

This study is completed. It is testing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8189 for schizophrenia.
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
This summary needs review. Please check the official study record and contact the research team for details.
Check the official source, then confirm these points with the research team.
View official study record (opens in a new tab)Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
View official study record (opens in a new tab)No specific site is confirmed in the available information. Check the official source for locations and remote participation.
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Confirm the location and whether remote participation is possible with the research team.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
This study is exploring psychotherapy or therapy for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
This appears to be a behavioral / psychological / psychosocial study involving Elpipodect, Placebo, Base Monotherapy. Phase 1 studies usually focus mainly on safety, tolerability, dosage, and side effects. They often involve healthy volunteers, but not always. Some Phase 1 studies include people living with the target condition.
This study may concern people with schizophrenia; age range: From 18 Years to 60 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
You may take part in sessions or exercises related to habits, thoughts, emotions, or behaviors. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
Behavioral studies can involve habits, emotions, motivation, stress, sleep, or ways of thinking. Ask whether the intervention could affect your mood or stress, and who to contact if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
This study is sponsored by Merck Sharp & Dohme LLC, which appears to be another type of organization. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me